Ganetespib, a second generation HSP90 inhibitor, effectively and simultaneously destabilizes HSP90 client proteins in NSCLC cells including receptor tyrosine kinases and canonical JAK/STAT, PI3K/AKT, MAPK and mTOR signaling. This evidence concerns the gene SOAT1 and non-small cell lung carcinoma.